Immune protection conferred by recombinant MRLC (myosin regulatory light chain) antigen in TiterMax Gold registered adjuvant against experimental fasciolosis in rats

Immune protection conferred by recombinant MRLC (myosin regulatory light chain) antigen in TiterMax Gold registered adjuvant against experimental fasciolosis in rats

Protection against experimental fasciolosis in rats immunized with recombinant myosin regulatory light chain (MRLC) in TiterMax Gold registered adjuvant was assessed. The experimental trial consisted of four groups of 15 animals; group 1 was unimmunized and infected, group 2 was immunized with MRLC...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2017-01, Vol.35 (4), p.663-671
Hauptverfasser: Henker, Luan C, Schwertz, Claiton I, Lucca, Neuber J, Piva, Manoela M, Prior, Keila C, Baska, Piotr, Norbury, Luke, Januszkiewicz, Kamil, Dezen, Diogenes, Duarte, Marta MMF, Moresco, Rafael N, Bertagnolli da Rosa, Liana, Mendes, Ricardo E
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Protection against experimental fasciolosis in rats immunized with recombinant myosin regulatory light chain (MRLC) in TiterMax Gold registered adjuvant was assessed. The experimental trial consisted of four groups of 15 animals; group 1 was unimmunized and infected, group 2 was immunized with MRLC in adjuvant and infected, group 3 was infected and immunized with adjuvant only and group 4 was unimmunized and uninfected. Immunization with MRLC in TiterMax Gold registered adjuvant (group 2) induced a reduction in fluke burdens of 51.0% (p
ISSN:0264-410X
DOI:10.1016/j.vaccine.2016.11.092